Current perspectives of biotechnological replacement of insulin secreting cells

Key words:

Genetic engineering - β-cell replacement, transplantation

References

• 1 Bailey C J, Davies E L, Docherty K. Prospects for insulin delivery by ex-vivo somatic cell gene therapy.  J Mol Med . 97 (in press), 2000; 
• 2 Bretzel R G, Hopt U T, Schatz H. Transplantations in patients with diabetes mellitus.  Exp Clin Endo Diabetes. 108 241-243 2000; 
• 3 Efrat S. Cell-based therapy for insulin-dependent diabetes mellitus.  European Journal of Endocrinology. 138 129-133 1998; 
• 4 Falqui L, Berra C, Severini G M, Martinengli S, Monti L D, Taglietti V, Pozza G, Bordignon C. Production of mature human insulin by retrovirally engineered fibroblasts and primary hepatocytes.  Exp Clin Endo Diabetes. 104 A36 1996; 
• 5 Ferber S, Halkin A, Cohen H, Ber I, Einav Y, Goldberg I, Barshack I, Seijfers R, Kopolovic J, Kaiser N, Karasik A. Pancreatic and duodenal homeobox gene 1 induces expression of insulin genes in liver and ameliorates steptozotocin-induced hyperglycemia.  Nature Medicine. 6 568-572 1999; 
• 6 Lipes M A, Davalli A M, Cooper E M. Genetic engineering of insulin expression in nonislet-cells: implications for β-cell replacement therapy for insulin-dependent diabetes mellitus.  Acta Diabetologia. 34 2-5 1997; 
• 7 Moore H-P H, Walker M D, Lee F, Kelly R B. Expressing a human proinsulin cDNA in a mouse ACTH secreting cell.  Cell. 35 531-538 1983; 
• 8 Newgard C B. Cellular engineering and gene therapy strategies for insulin replacement in diabetes.  Diabetes. 43 341-350 1994; 
• 9 Pfeiffer E F. The “Ulm Zucker Uhr” system and its consequences.  Horm Metab Res. 26 510-515 1994; 
• 10 Tietge M, Lenzen S. Gene therapy of diabetes mellitus - aims, methods and future prospects.  Experimental Clinical Endocrinology & Diabetes. 103 46-55 1995;